10 Best Penny Stocks to Buy Before They Explode

8. MannKind Corporation (NASDAQ:MNKD)

On May 7, 2026, Wells Fargo raised the firm’s price target on MannKind Corporation (NASDAQ:MNKD) to $10 from $8 while maintaining an Overweight rating following disclosure of the company’s involvement with ralinepag DPI and ahead of upcoming PDUFA decisions tied to Afrezza and Furoscix. The firm said it now sees multiple potential avenues for revenue growth.

Similarly, H.C. Wainwright raised its price target on MannKind Corporation (NASDAQ:MNKD) to $10 from $8 while maintaining a Buy rating. The firm said Q1 results came in below expectations, though that does not alter its broader investment thesis, which is increasingly centered on the durability and upside potential of MannKind’s royalty and collaboration revenue streams. H.C. Wainwright also cited potential pipeline upside in support of the target increase.

A day earlier, MannKind Corporation (NASDAQ:MNKD) reported Q1 EPS of (2c), versus the consensus estimate of 1c. Revenue totaled $90.17M, versus the consensus estimate of $105.31M. CEO Michael Castagna said the company continues making progress on its corporate transformation strategy focused on expanding and diversifying both its commercial portfolio and development pipeline. Castagna described 2026 as the most catalyst-rich year in MannKind’s history. Castagna added that potential approval of the Furoscix ReadyFlow Autoinjector could help accelerate the brand’s growth trajectory, while a potential pediatric expansion for Afrezza could address unmet needs in a new patient population. Castagna also pointed to continued momentum from Tyvaso DPI, including expansion into IPF, along with the company’s expanded collaboration with United Therapeutics involving ralinepag DPI.

MannKind Corporation (NASDAQ:MNKD) is a biopharmaceutical company focused on developing therapies and technologies for chronic disease care.